OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
PARSIPPANY, N.J., April 27, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 4, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 4977296. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 4977296. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
